Study of the Differential Activity of Thrombin Inhibitors Using Docking, QSAR, Molecular Dynamics, and MM-GBSA

Non-peptidic thrombin inhibitors (TIs; 177 compounds) with diverse groups at motifs P1 (such as oxyguanidine, amidinohydrazone, amidine, amidinopiperidine), P2 (such as cyanofluorophenylacetamide, 2-(2-chloro-6-fluorophenyl)acetamide), and P3 (such as phenylethyl, arylsulfonate groups) were studied using molecular modeling to analyze their interactions with S1, S2, and S3 subsites of the thrombin binding site. Firstly, a protocol combining docking and three dimensional quantitative structure–activity relationship was performed. We described the orientations and preferred active conformations of the studied inhibitors, and derived a predictive CoMSIA model including steric, donor hydrogen bond, and acceptor hydrogen bond fields. Secondly, the dynamic behaviors of some selected TIs (compounds 26, 133, 147, 149, 162, and 177 in this manuscript) that contain different molecular features and different activities were analyzed by creating the solvated models and using molecular dynamics (MD) simulations. We used the conformational structures derived from MD to accomplish binding free energetic calculations using MM-GBSA. With this analysis, we theorized about the effect of van der Waals contacts, electrostatic interactions and solvation in the potency of TIs. In general, the contents reported in this article help to understand the physical and chemical characteristics of thrombin-inhibitor complexes.

[1]  P. Kollman,et al.  Computational study of protein specificity: The molecular basis of HIV-1 protease drug resistance , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[2]  Kenichi A Tanaka,et al.  Blood Coagulation: Hemostasis and Thrombin Regulation , 2009, Anesthesia and analgesia.

[3]  Julio Caballero,et al.  Study of the Affinity between the Protein Kinase PKA and Peptide Substrates Derived from Kemptide Using Molecular Dynamics Simulations and MM/GBSA , 2014, PloS one.

[4]  B. Tomczuk,et al.  Structure-activity and crystallographic analysis of a new class of non-amide-based thrombin inhibitor. , 2000, Bioorganic & medicinal chemistry letters.

[5]  Julio Caballero,et al.  Docking and quantitative structure–activity relationship studies for sulfonyl hydrazides as inhibitors of cytosolic human branched-chain amino acid aminotransferase , 2009, Molecular Diversity.

[6]  L. Lima,et al.  Structure and Behavior of Human α-Thrombin upon Ligand Recognition: Thermodynamic and Molecular Dynamics Studies , 2011, PloS one.

[7]  Mark R Player,et al.  2-(2-Chloro-6-fluorophenyl)acetamides as potent thrombin inhibitors. , 2007, Bioorganic & medicinal chemistry letters.

[8]  Bernard R. Brooks,et al.  New spherical‐cutoff methods for long‐range forces in macromolecular simulation , 1994, J. Comput. Chem..

[9]  B. Tomczuk,et al.  Oxyguanidines: application to non-peptidic phenyl-based thrombin inhibitors. , 2003, Bioorganic & medicinal chemistry letters.

[10]  Jans H. Alzate-Morales,et al.  Study of differences in the VEGFR2 inhibitory activities between semaxanib and SU5205 using 3D-QSAR, docking, and molecular dynamics simulations. , 2012, Journal of molecular graphics & modelling.

[11]  J. Hirsh,et al.  Translational Success Stories: Development of Direct Thrombin Inhibitors , 2012, Circulation research.

[12]  Anil K. Saxena,et al.  Profiling the Structural Determinants for the Selectivity of Representative Factor-Xa and Thrombin Inhibitors Using Combined Ligand-Based and Structure-Based Approaches , 2011, J. Chem. Inf. Model..

[13]  P. Kollman,et al.  Combined molecular mechanical and continuum solvent approach (MM-PBSA/GBSA) to predict ligand binding , 2000 .

[14]  B. Tomczuk,et al.  Non-peptidic phenyl-based thrombin inhibitors: exploring structural requirements of the S1 specificity pocket with amidines. , 2000, Bioorganic & medicinal chemistry letters.

[15]  Jans H. Alzate-Morales,et al.  Performance of the MM/GBSA scoring using a binding site hydrogen bond network-based frame selection: the protein kinase case. , 2014, Physical chemistry chemical physics : PCCP.

[16]  Tingjun Hou,et al.  Molecular dynamics and free energy studies on the wild-type and double mutant HIV-1 protease complexed with amprenavir and two amprenavir-related inhibitors: mechanism for binding and drug resistance. , 2007, Journal of medicinal chemistry.

[17]  B. Tomczuk,et al.  Amidinohydrazones as guanidine bioisosteres: application to a new class of potent, selective and orally bioavailable, non-amide-based small-molecule thrombin inhibitors. , 2000, Bioorganic & medicinal chemistry letters.

[18]  B. Tomczuk,et al.  Oxyguanidines. Part 2: Discovery of a novel orally active thrombin inhibitor through structure-based drug design and parallel synthesis. , 2004, Bioorganic & medicinal chemistry letters.

[19]  Arthur M. Doweyko,et al.  3D-QSAR illusions , 2004, J. Comput. Aided Mol. Des..

[20]  G. Klebe,et al.  Enhancement of hydrophobic interactions and hydrogen bond strength by cooperativity: synthesis, modeling, and molecular dynamics simulations of a congeneric series of thrombin inhibitors. , 2010, Journal of medicinal chemistry.

[21]  Laxmikant V. Kalé,et al.  Scalable molecular dynamics with NAMD , 2005, J. Comput. Chem..

[22]  Corwin Hansch,et al.  An approach toward the problem of outliers in QSAR. , 2005, Bioorganic & medicinal chemistry.

[23]  P. Carrupt,et al.  Synthesis and biological evaluation of direct thrombin inhibitors bearing 4-(piperidin-1-yl)pyridine at the P1 position with potent anticoagulant activity. , 2013, Journal of medicinal chemistry.

[24]  G. Klebe,et al.  Knowledge-based scoring function to predict protein-ligand interactions. , 2000, Journal of molecular biology.

[25]  Alexander D. MacKerell,et al.  All-atom empirical potential for molecular modeling and dynamics studies of proteins. , 1998, The journal of physical chemistry. B.

[26]  Julio Caballero,et al.  Structural requirements of pyrido[2,3-d]pyrimidin-7-one as CDK4/D inhibitors: 2D autocorrelation, CoMFA and CoMSIA analyses. , 2008, Bioorganic & medicinal chemistry.

[27]  Yujie Ren,et al.  Design, synthesis and structural exploration of novel fluorinated dabigatran derivatives as direct thrombin inhibitors. , 2015, European journal of medicinal chemistry.

[28]  W. L. Jorgensen,et al.  Comparison of simple potential functions for simulating liquid water , 1983 .

[29]  Matthew P. Repasky,et al.  Glide: a new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy. , 2004, Journal of medicinal chemistry.

[30]  B. Tomczuk,et al.  Discovery and clinical evaluation of 1-{N-[2-(amidinoaminooxy)ethyl]amino}carbonylmethyl-6-methyl-3-[2,2-difluoro-2-phenylethylamino]pyrazinone (RWJ-671818), a thrombin inhibitor with an oxyguanidine P1 motif. , 2010, Journal of medicinal chemistry.

[31]  C. Kontogiorgis,et al.  Quantitative structure -- activity relationships (QSARs) of thrombin inhibitors: review, evaluation and comparative analysis. , 2003, Current medicinal chemistry.

[32]  M. Hämäläinen,et al.  Compounds binding to the S2-S3 pockets of thrombin. , 2009, Journal of medicinal chemistry.

[33]  I. Melnikova The anticoagulants market , 2009, Nature Reviews Drug Discovery.

[34]  B. Tomczuk,et al.  Orally efficacious thrombin inhibitors with cyanofluorophenylacetamide as the P2 motif. , 2008, Bioorganic & medicinal chemistry letters.

[35]  P. Shekelle,et al.  Venous Thromboembolism Prophylaxis in Hospitalized Patients: A Clinical Practice Guideline From the American College of Physicians , 2011, Annals of Internal Medicine.

[36]  G Klebe,et al.  Three-dimensional quantitative structure-activity relationship analyses using comparative molecular field analysis and comparative molecular similarity indices analysis to elucidate selectivity differences of inhibitors binding to trypsin, thrombin, and factor Xa. , 1999, Journal of medicinal chemistry.

[37]  Julio Caballero,et al.  Protective mechanisms of adenosine 5′-monophosphate in platelet activation and thrombus formation , 2013, Thrombosis and Haemostasis.

[38]  J. Correa-Basurto,et al.  Exploring QSARs for inhibitory effect of a set of heterocyclic thrombin inhibitors by multilinear regression refined by artificial neural network and molecular docking simulations , 2012, Journal of enzyme inhibition and medicinal chemistry.

[39]  Julio Caballero,et al.  Binding Studies and Quantitative Structure–Activity Relationship of 3‐Amino‐1H‐Indazoles as Inhibitors of GSK3β , 2011, Chemical biology & drug design.

[40]  B. Tomczuk,et al.  In vitro evaluation and crystallographic analysis of a new class of selective, non-amide-based thrombin inhibitors. , 1998, Bioorganic & medicinal chemistry letters.

[41]  S. Deswal,et al.  Quantitative structure activity relationship studies of aryl heterocycle-based thrombin inhibitors. , 2006, European journal of medicinal chemistry.

[42]  Alexander D. MacKerell,et al.  CHARMM general force field: A force field for drug‐like molecules compatible with the CHARMM all‐atom additive biological force fields , 2009, J. Comput. Chem..

[43]  H. Gohlke,et al.  Free Energy Calculations by the Molecular Mechanics Poisson−Boltzmann Surface Area Method , 2012, Molecular informatics.

[44]  Mirko Zimic,et al.  Docking and quantitative structure–activity relationship studies for 3-fluoro-4-(pyrrolo[2,1-f][1,2,4]triazin-4-yloxy)aniline, 3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)aniline, and 4-(4-amino-2-fluorophenoxy)-2-pyridinylamine derivatives as c-Met kinase inhibitors , 2011, J. Comput. Aided Mol. Des..

[45]  Bruce L. Bush,et al.  Sample-distance partial least squares: PLS optimized for many variables, with application to CoMFA , 1993, J. Comput. Aided Mol. Des..